Fan Pep <4881> announced that it will record a subsidy income of 10 million yen for the cumulative period of the third quarter of the fiscal year ending December 2024 (January-September 2024). This is based on the re-contracted research and development agreement related to the practical application of IL-17A vaccine (FPP003) targeting ankylosing spondylitis, which was adopted by Osaka University from the Japan Agency for Medical Research and Development (AMED). It was previously recorded as deferred income due to the receipt of re-contracted fees from Osaka University, but it was transferred to non-operating income for the fiscal year as they received notification of the confirmed inspection results for the 2023 fiscal year from Osaka University.